PVLA · Palvella Therapeutics, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 23, 2024; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Palvella initiated the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations (first module submitted) and remains on track to complete the submission in 2H 2026 and target potential FDA approval in 1H 2027, while also planning a Phase 3 start in cutaneous venous malformations in Q4 2026, expanding its launch sales force to ~40 reps and guiding to $85–$95M of 2026 cash spend off a $251M cash balance.
- + Rolling NDA initiated with first module submitted and completion on track for 2H 2026, targeting potential FDA approval in 1H 2027
- + Strong balance sheet of $250.6M provides runway through potential launch
- + Planned launch sales force expanded to ~40 reps at upper end of prior range
- + Phase 2 LOTU in angiokeratomas dosing initiated with topline data expected 2H 2027; Phase 2 DSAP study also planned for 2H 2026
- − 2026 cash burn guidance raised to $85–$95M following launch-readiness and pipeline expansion
- − Q2 net loss widened to $21.9M versus $9.5M prior year, driven by higher R&D and G&A
- − FDA did not initially grant Breakthrough Therapy designation for cutaneous venous malformations
- − R&D expenses more than doubled to $12.5M and G&A more than doubled to $8.9M year over year
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PVLA
this stock
Palvella Therapeutics, Inc.
|
$2.16B | +43.4% | +65.3% | — | 15.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 23, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PVLA | -3.4% | -4.1% | +33.5% | -1.6% | +43.4% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.3% | -2.4% | +15.6% | -1.3% | +31.4% |